Moderna Will Supply Gavi with up to 500 Million Doses of its COVID-19 Vaccine
The company will provide the vaccine group with 34 million doses in the fourth quarter of this year, and up to 466 million more doses in 2022.
Moderna announced it has an agreement with Gavi, the Vaccine Alliance, to supply up to 500 million doses to 92 low and middle income countries, at the company’s lowest tiered price.
Gavi is a public-private partnership that helps vaccinate children against some of the world’s deadliest diseases. This agreement falls within Gavi’s global COVAX initiative which is trying to ensure access to COVID-19 vaccines to all countries no matter their income levels. COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, is co-led by CEPI, Gavi, and WHO—working in partnership with UNICEF and PAHO as delivery partners, developed and developing country vaccine manufacturers, the World Bank, and others.
“We are very pleased to sign this new agreement with Moderna, giving COVAX Facility participants access to yet another highly efficacious vaccine,” Gavi CEO Seth Berkley, MD, said. “Expanding and having a diverse portfolio has always been a core goal for COVAX, and to remain adaptable in the face of this continually evolving pandemic–including the rising threat posed by new variants. This agreement is a further step in that direction.”
Moderna’s COVID-19 vaccine has recently received an Emergency Use Listing from the WHO, making it eligible to be supplied to COVAX Facility participants. Supply via this APA is expected to commence in Q4 2021. The agreement also contains options to potentially access doses of variant-adapted vaccine in the future.
All doses were offered at Moderna’s lowest tiered price, in line with the Company’s global access commitments
“I am grateful to our Gavi and COVAX partners for their tireless work and to the entire Moderna team for their collaboration to reach this agreement. This is an important milestone as we work to ensure that people around the world have access to our COVID-19 vaccine,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We recognize that many countries have limited resources to access COVID-19 vaccines. We support COVAX’s mission to ensure broad, affordable and equitable access to COVID-19 vaccines and we remain committed to doing everything that we can to ending this ongoing pandemic with our mRNA COVID-19 vaccine.”